Clinical Implications of Intestinal Barrier Damage in Psoriasis

References

• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi:10.1111/bjd.18245
   PubMed Web of Science ®Google Scholar
• Tong Y, Marion T, Schett G, Luo Y, Liu Y. Microbiota and metabolites in rheumatic diseases. Autoimmun Rev. 2020;19(8):102530. doi:10.1016/j.autrev.2020.102530
   PubMed Web of Science ®Google Scholar
• Tajik N, Frech M, Schulz O, et al. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11(1):1995. doi:10.1038/s41467-020-15831-7
   PubMed Web of Science ®Google Scholar
• Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516–1526. doi:10.1136/gutjnl-2019-318427
   PubMed Web of Science ®Google Scholar
• Gomez-Hurtado I, Gallego-Duran R, Zapater P, et al. Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. Liver Int. 2020. doi:10.1111/liv.14571
   PubMed Web of Science ®Google Scholar
• Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54. doi:10.1038/s41577-019-0198-4
   PubMed Web of Science ®Google Scholar
• Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179(1):16–29. doi:10.1111/bjd.16239
   PubMed Web of Science ®Google Scholar
• Sikora M, Stec A, Chrabaszcz M, et al. Gut microbiome in psoriasis: an updated review. Pathogens. 2020;9(6):463. doi:10.3390/pathogens9060463
   PubMed Web of Science ®Google Scholar
• Sikora M, Stec A, Chrabaszcz M, et al. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J Clin Med. 2019;8(7). doi:10.3390/jcm8071021
   PubMed Web of Science ®Google Scholar
• Stehlikova Z, Kostovcik M, Kostovcikova K, et al. Dysbiosis of skin microbiota in psoriatic patients: co-occurrence of fungal and bacterial communities. Front Microbiol. 2019;10:438. doi:10.3389/fmicb.2019.00438
   PubMed Web of Science ®Google Scholar
• Gerdes S, Osadtschy S, Buhles N, Mrowietz U. Zonulin may not be a marker of autoimmunity in patients with psoriasis. Acta Derm Venereol. 2012;92(2):171–172. doi:10.2340/00015555-1208
   PubMed Web of Science ®Google Scholar
• Richetta AG, Grassi S, Moliterni E, et al. Increased intestinal barrier permeability in patients with moderate to severe plaque-type psoriasis. J Dermatol. 2020;47(10). doi:10.1111/1346-8138.15361
   PubMed Web of Science ®Google Scholar
• Sikora M, Chrabaszcz M, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019;33(10):1907–1912. doi:10.1111/jdv.15700
   PubMed Web of Science ®Google Scholar
• Sikora M, Chrabaszcz M, Maciejewski C, et al. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018;45(12):1468–1470. doi:10.1111/1346-8138.14647
   PubMed Web of Science ®Google Scholar
• Romani J, Caixas A, Escote X, et al. Lipopolysaccharide-binding protein is increased in patients with psoriasis with metabolic syndrome, and correlates with C-reactive protein. Clin Exp Dermatol. 2013;38(1):81–84. doi:10.1111/ced.12007
   PubMed Web of Science ®Google Scholar
• Codoner FM, Ramirez-Bosca A, Climent E, et al. Gut microbial composition in patients with psoriasis. Sci Rep. 2018;8(1):3812. doi:10.1038/s41598-018-22125-y
   PubMed Web of Science ®Google Scholar
• Ramirez-Bosca A, Navarro-Lopez V, Martinez-Andres A, et al. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151(6):670–671. doi:10.1001/jamadermatol.2014.5585
   PubMed Web of Science ®Google Scholar
• Feldman SR, Srivastava B, Abell J, et al. Gastrointestinal signs and symptoms related to inflammatory bowel disease in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2018;17(12):1298–1308.
   PubMed Web of Science ®Google Scholar
• Ganda Mall JP, Ostlund-Lagerstrom L, Lindqvist CM, et al. Are self-reported gastrointestinal symptoms among older adults associated with increased intestinal permeability and psychological distress? BMC Geriatr. 2018;18(1):75. doi:10.1186/s12877-018-0767-6
   PubMedGoogle Scholar
• Karhu E, Forsgard RA, Alanko L, et al. Exercise and gastrointestinal symptoms: running-induced changes in intestinal permeability and markers of gastrointestinal function in asymptomatic and symptomatic runners. Eur J Appl Physiol. 2017;117(12):2519–2526. doi:10.1007/s00421-017-3739-1
   PubMed Web of Science ®Google Scholar
• Linsalata M, Riezzo G, D’Attoma B, Clemente C, Orlando A, Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterol. 2018;18(1):167. doi:10.1186/s12876-018-0888-6
   PubMedGoogle Scholar
• Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol. 2010;1(3):97–105. doi:10.4291/wjgp.v1.i3.97
   PubMedGoogle Scholar
• Adarsh MB, Dogra S, Vaiphei K, Vaishnavi C, Sinha SK, Sharma A. Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. Br J Dermatol. 2019;181(2):401–402. doi:10.1111/bjd.17745
   PubMed Web of Science ®Google Scholar
• Nowinski A, Ufnal M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases? Nutrition. 2018;46:7–12. doi:10.1016/j.nut.2017.08.001
   PubMed Web of Science ®Google Scholar
• Ufnal M, Zadlo A, Ostaszewski R. TMAO: a small molecule of great expectations. Nutrition. 2015;31(11–12):1317–1323. doi:10.1016/j.nut.2015.05.006
   PubMed Web of Science ®Google Scholar
• Farhangi MA, Vajdi M. Novel findings of the association between gut microbiota-derived metabolite trimethylamine N-oxide and inflammation: results from a systematic review and dose-response meta-analysis. Crit Rev Food Sci Nutr. 2020;60(16):2801–2823. doi:10.1080/10408398.2020.1770199
   PubMed Web of Science ®Google Scholar
• Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. 2019;10:1360. doi:10.3389/fphar.2019.01360
   PubMed Web of Science ®Google Scholar
• Dehghan P, Farhangi MA, Nikniaz L, Nikniaz Z, Asghari-Jafarabadi M. Gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) potentially increases the risk of obesity in adults: an exploratory systematic review and dose-response meta- analysis. Obes Rev. 2020;21(5):e12993. doi:10.1111/obr.12993
   PubMed Web of Science ®Google Scholar
• Ge X, Zheng L, Zhuang R, et al. The gut microbial metabolite trimethylamine N-oxide and hypertension risk: a systematic review and dose-response meta-analysis. Adv Nutr. 2020;11(1):66–76. doi:10.1093/advances/nmz064
   PubMed Web of Science ®Google Scholar
• Papandreou C, More M, Bellamine A. Trimethylamine N-oxide in relation to cardiometabolic health—cause or effect? Nutrients. 2020;12(5):1330. doi:10.3390/nu12051330
   PubMed Web of Science ®Google Scholar
• Leon-Mimila P, Villamil-Ramirez H, Li XS, et al. Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. Diabetes Metab. 2020. doi:10.1016/j.diabet.2020.07.010
   PubMedGoogle Scholar
• Roy S, Yuzefpolskaya M, Nandakumar R, Colombo PC, Demmer RT, Hu C. Plasma trimethylamine-N-oxide and impaired glucose regulation: results from the Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS). PLoS One. 2020;15(1):e0227482. doi:10.1371/journal.pone.0227482
   PubMed Web of Science ®Google Scholar
• Coras R, Kavanaugh A, Boyd T, et al. Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. Clin Exp Rheumatol. 2019;37(3):481–484.
   PubMed Web of Science ®Google Scholar
• Jaworska K, Bielinska K, Gawrys-Kopczynska M, Ufnal M. TMA (trimethylamine), but not its oxide TMAO (trimethylamine-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome. Cardiovasc Res. 2019;115(14):1948–1949. doi:10.1093/cvr/cvz231
   PubMed Web of Science ®Google Scholar
• Jaworska K, Hering D, Mosieniak G, et al. TMA, A forgotten uremic toxin, but not TMAO, is involved in cardiovascular pathology. Toxins (Basel). 2019;11(9):490. doi:10.3390/toxins11090490
   PubMed Web of Science ®Google Scholar
• Ufnal M, Jazwiec R, Dadlez M, Drapala A, Sikora M, Skrzypecki J. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol. 2014;30(12):1700–1705. doi:10.1016/j.cjca.2014.09.010
   PubMed Web of Science ®Google Scholar
• Wolyniec W, Kasprowicz K, Giebultowicz G, et al. Changes in water soluble uremic toxins and urinary acute kidney injury biomarkers after 10- and 100-km runs. Int J Environ Res Public Health. 2019;16(21):4153. doi:10.3390/ijerph16214153
   PubMed Web of Science ®Google Scholar
• Kulich KR, Regula J, Stasiewicz J, et al. Psychometric validation of the polish translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in patients with reflux disease. Pol Arch Med Wewn. 2005;113(3):241–249.
   PubMedGoogle Scholar
• Kulich KR, Madisch A, Pacini F, et al. Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008;6(1):12. doi:10.1186/1477-7525-6-12
   PubMedGoogle Scholar